Skip to main content

Advertisement

SpringerLink
Log in

Retrospective analysis of first-line treatment for follicular lymphoma based on outcomes and medical economics

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

Follicular lymphoma (FL) is the most common type of non-Hodgkin lymphoma (NHL), with indolent progression. Several treatment options are selected, based not only on disease status, quality of life (QOL), and age of patient, but also on recent increasing medical costs. We retrospectively analysed the first-line treatment of FL with regard to treatment outcomes and medical economics, and discuss the appropriate strategies for FL.

Methods

Data on a total of 69 newly-diagnosed patients with FL was retrospectively collected from 2001 to 2015.

Results

The median age of the patients was 60 years and the median follow-up was 58 months. A total of 25 cases with FL were treated with R monotherapy, and 28 cases were treated with R-CHOP as first-line treatment. The factors affecting the decision of physicians to use R or R-CHOP treatment were serum level of lactate dehydrogenase (LDH) and disease stage. The first-line treatment-associated survival did not show any statistical differences between R and R-CHOP. The average hospitalization and average of all medical costs during the first-line treatment were 4.1 days (R) versus 55.7 days (R-CHOP), and JPY 1,707,693 (USD 15,324) (R) versus JPY 2,136,117 (USD 19,170) (R-CHOP), respectively.

Conclusion

R monotherapy for patients whose diseases show low tumor burden and who are not candidates for local treatment has benefits as a first-line treatment compared to R-CHOP, based on the patients’ QOL and medical economics.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Lo Coco F, Gaidano G, Louie DC et al (1993) P53 mutations are associated with histologic transformation of follicular lymphoma. Blood 82:2289–2295

    CAS  PubMed  Google Scholar 

  2. Elenitoba-Johnson KS, Gascoyne RD, Lim MS et al (1998) Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma. Blood 91:4677–4685

    CAS  PubMed  Google Scholar 

  3. Pinyol M, Cobo F, Bea S et al (1998) P16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin’s lymphomas. Blood 91:2977–2984

    CAS  PubMed  Google Scholar 

  4. Lossos IS, Alizadeh AA, Diehn M et al (2002) Transformation of follicular lymphoma to diffuse large-cell lym-phoma: alternative patterns with increased or decreased expression of c-myc and its regulated genes. Proc Natl Acad Sci USA 99:8886–8891

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Akasaka T, Lossos IS, Levy R (2003) BCL6 gene translocation in follicular lymphoma: a harbinger of eventual transformation to diffuse aggressive lymphoma. Blood 102:1443–1448

    Article  CAS  PubMed  Google Scholar 

  6. Brodtkorb M, Lingjaerde OC, Huse K et al (2014) Whole-genome integrative analysis reveals expression signatures predicting transformation in follicular lymphoma. Blood 123:1051–1054

    Article  CAS  PubMed  Google Scholar 

  7. Vasishtha M, Messina M, Holmes AB et al (2014) Genetics of follicular lymphoma transformation. Cell Rep 6:130–140

    Article  PubMed  PubMed Central  Google Scholar 

  8. Bai B, Huang HQ (2015) Individualized management of follicular lymphoma. Chin Clin Oncol 4:7. doi:10.3978/j.issn.2304-3865.2015.01.01

    PubMed  Google Scholar 

  9. Izutsu K (2014) Treatment of follicular lymphoma. J Clin Exp Hematop 54:31–37

    Article  PubMed  Google Scholar 

  10. Hiddemann W, Cheson BD (2014) How we manage follicular lymphoma. Leukemia 28:1388–1395

    Article  CAS  PubMed  Google Scholar 

  11. Kenkre VP, Kahl BS (2012) What is the best initial therapy for a patient with symptomatic low-grade follicular lymphoma? Cancer J 18:383–389

    Article  CAS  PubMed  Google Scholar 

  12. Bello C, Zhang L, Naghashpour M (2012) Follicular lymphoma: current management and future directions. Cancer Control 19:187–195

    Article  PubMed  Google Scholar 

  13. Salles G, Ghesquières H, Bachy E (2012). What is the best first-line treatment strategy for patients with indolent lymphomas? Am Soc Clin Oncol Educ Book, pp 488–493

  14. McLaughlin P (2011) Management options for follicular lymphoma: observe; R-CHOP; B-R; others? Clin Lymphoma Myeloma Leuk 11(Suppl 1):S91–S95. doi:10.1016/j.clml.2011.04.006

    Article  PubMed  Google Scholar 

  15. van Agthoven M, Kramer MH, Sonneveld P et al (2005) Cost analysis of common treatment options for indolent follicular non-Hodgkin’s lymphoma. Haematologica 90:1422–1432

    PubMed  Google Scholar 

  16. Schmitz S, Aly F, Steinmetz T et al (2006) Sensitivity analysis of cost factors for various therapy options in the treatment of follicular lymphoma. Onkologie 29:258–264

    PubMed  Google Scholar 

  17. Soini EJ, Martikainen JA, Vihervaara V et al (2012) Economic evaluation of sequential treatments for follicular non-Hodgkin lymphoma. Clin Ther 34:915–925

    Article  PubMed  Google Scholar 

  18. Johnston KM, Bolbocean C, Connors J et al (2012) Cost-effectiveness of rituximab in follicular lymphoma. Expert Rev Pharmacoecon Outcomes Res 12:569–577

    Article  PubMed  Google Scholar 

  19. Prica A, Chan K, Cheung M (2015) Frontline rituximab monotherapy induction versus a watch and wait approach for asymptomatic advanced-stage follicular lymphoma: a cost-effectiveness analysis. Cancer 121:2637–2645

    Article  CAS  PubMed  Google Scholar 

  20. Danese MD, Reyes CM, Gleeson ML et al (2016) Estimating the population benefits and costs of rituximab therapy in the United States from 1998 to 2013 using real-world data. Med Care 54:343–349

    Article  PubMed  PubMed Central  Google Scholar 

  21. Solal-Céligny P, Roy P, Colombat P et al (2004) Follicular lymphoma international prognostic index. Blood 104:1258–1265

    Article  PubMed  Google Scholar 

  22. Milanovic N, Matkovic S, Ristic D et al (2012) Significance of tumor burden, vascular endothelial growth factor, lactate dehydrogenase and beta-2 microglobulin serum levels in advanced diffuse large B cell lymphoma. J BUON 17:497–501

    CAS  PubMed  Google Scholar 

  23. Kahl BS, Hong F, Williams ME et al (2014) Rituximab extended schedule or re-treatment trial for low tumor burden follicular lymphoma: Eastern Cooperative Oncology Group protocol E4402. J Clin Oncol 32:3096–3102

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Palla AR, Hamadani M (2013) Rituximab maintenance versus retreatment in follicular lymphoma. Hematol Oncol 31:171–178

    Article  CAS  PubMed  Google Scholar 

  25. Johnston A, Bouafia-Sauvy F, Broussais-Guillaumot F et al (2009) Retreatment with rituximab in 178 patients with relapsed and refractory B-cell lymphomas: a single institution case control study. Leuk Lymph 51:399–405

    Article  Google Scholar 

  26. Rummel MJ, Niederle N, Maschmeyer G et al (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381:1203–1210

    Article  CAS  PubMed  Google Scholar 

  27. Flinn IW, van der Jagt R, Kahl BS et al (2014) Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 123:2944–2952

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We appreciate the cooperation of the staff members of the chemotherapy room in Ehime University Hospital.

Author information

Authors and Affiliations

  1. Department of Clinical Oncology, Ehime University School of Medicine, Toon, Japan

    Manaka Muneishi & Ayaka Nakamura

  2. Medical Profession Division, Ehime University Hospital, Toon, Japan

    Katsumi Tachibana & Junko Suemitsu

  3. Department of Clinical Oncology, Ehime University Graduate School of Medicine, Toon, Japan

    Shinji Hasebe & Yoshihiro Yakushijin

  4. Cancer Center, Ehime University Hospital, Toon, Japan

    Kazuto Takeuchi & Yoshihiro Yakushijin

Authors
  1. Manaka Muneishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ayaka Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Katsumi Tachibana
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Junko Suemitsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shinji Hasebe
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kazuto Takeuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yoshihiro Yakushijin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yoshihiro Yakushijin.

Ethics declarations

Conflict of interest

The authors have no conflict of interest.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Muneishi, M., Nakamura, A., Tachibana, K. et al. Retrospective analysis of first-line treatment for follicular lymphoma based on outcomes and medical economics. Int J Clin Oncol 23, 375–381 (2018). https://doi.org/10.1007/s10147-017-1202-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-017-1202-2

Keywords

Search

Navigation